Am J Gastroenterol

1. SAMALA N, Xin Y, Wilson LA, Yates K, et al
   Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype.
   Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002756.
   

   >> Share

   
   

   
   Biochem Biophys Res Commun

2. PENG J, Liang G, Li Y, Mao S, et al
   Identification of a novel FOXO3 agonist that protects against alcohol induced liver injury.
   Biochem Biophys Res Commun. 2024;704:149690.
   

   >> Share

   
   
3. SHANG S, Wan Q, Chen F, Hu J, et al
   Co-targeting ASK1 and THRbeta synergistically improves steatohepatitis and fibrosis in a MASH animal model.
   Biochem Biophys Res Commun. 2024;705:149739.
   

   >> Share

   
   

   
   BMC Cancer

4. PAN T, Li J, Zhang O, Zhu Y, et al
   Knockdown of ribosome RNA processing protein 15 suppresses migration of hepatocellular carcinoma through inhibiting PATZ1-associated LAMC2/FAK pathway.
   BMC Cancer. 2024;24:334.
   

   >> Share

   
   
5. LEE JH, Hong YM
   The relationship between tumor-infiltrating neutrophils and clinical outcomes in patients with resectable hepatocellular carcinoma.
   BMC Cancer. 2024;24:327.
   

   >> Share

   
   

   
   Br J Surg

6. MAJLESARA A, Golriz M, Ramouz A, Khajeh E, et al
   Portal vein arterialization as a salvage method in advanced hepatopancreatobiliary surgery.
   Br J Surg. 2024;111:znae053.
   

   >> Share

   
   

   
   Cancer Res

7. HUANG J, Tsang WY, Fang XN, Zhang Y, et al
   FASN Inhibition Decreases MHC-I Degradation and Synergizes with PD-L1 Checkpoint Blockade in Hepatocellular Carcinoma.
   Cancer Res. 2024;84:855-871.
   

   >> Share

   
   
8. WENG J, Wang Z, Hu Z, Xu W, et al
   Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy.
   Cancer Res. 2024 Mar 14. doi: 10.1158/0008-5472.CAN-23-3106.
   

   >> Share

   
   
9. LIAO H, Chen X, Wang H, Lin Y, et al
   Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers.
   Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-3298.
   

   >> Share

   
   
10. WAN S, He QY, Yang Y, Liu F, et al
    SPARC stabilizes ApoE to induce cholesterol-dependent invasion and sorafenib resistance in hepatocellular carcinoma.
    Cancer Res. 2024 Mar 12. doi: 10.1158/0008-5472.CAN-23-2889.
    

    >> Share

    
    

    
    Clin Res Hepatol Gastroenterol

11. AN Y, Xia Y, Wang Z, Jin GZ, et al
    Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2024;48:102289.
    

    >> Share

    
    
12. HAYAT HMS, Naeem H
    Aspirin for non alcoholic fatty liver disease: Promising but inconclusive-A letter to the editor.
    Clin Res Hepatol Gastroenterol. 2024;48:102286.
    

    >> Share

    
    
13. HOOSHMAND GHARABAGH L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A, et al
    Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102279.
    

    >> Share

    
    
14. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    

    >> Share

    
    
15. CHEN F, Chen C, Zhang Y, Jiang L, et al
    Bilateral optic atrophy in Wilson disease: A case report and literature review.
    Clin Res Hepatol Gastroenterol. 2024;48:102299.
    

    >> Share

    
    
16. RAN D, Xin C, Ma Y, Lu Y, et al
    Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components.
    Clin Res Hepatol Gastroenterol. 2024;48:102302.
    

    >> Share

    
    
17. LI B, Ren ZW, Zhang C, Yu XX, et al
    Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching.
    Clin Res Hepatol Gastroenterol. 2024;48:102298.
    

    >> Share

    
    
18. NDHLOVU E, Zhang BX, Chen XP, Zhu P, et al
    Thermal ablation for hepatic tumors in high-risk locations.
    Clin Res Hepatol Gastroenterol. 2024;48:102300.
    

    >> Share

    
    

    
    Dig Dis Sci

19. KAHN-BOESEL O, Mitchell H, Li L, Zhu E, et al
    Hospital-Level Care at Home for Patients with Cirrhosis.
    Dig Dis Sci. 2024 Mar 11. doi: 10.1007/s10620-024-08361.
    

    >> Share

    
    

    
    Endoscopy

20. HASSAN KM, Dawod E, Hassan M, Salgado SM, et al
    Endoscopic treatment of a hepatic abscess arising from a biliary stricture due to intraductal papillary neoplasm of the bile duct.
    Endoscopy. 2024;56.
    

    >> Share

    
    

    
    Eur Radiol

21. BYENFELDT M, Kihlberg J, Nasr P, Gronlund C, et al
    Altered probe pressure and body position increase diagnostic accuracy for men and women in detecting hepatic steatosis using quantitative ultrasound.
    Eur Radiol. 2024 Mar 8. doi: 10.1007/s00330-024-10655.
    

    >> Share

    
    
22. BOUATTOUR M, Vilgrain V, Sepulveda A
    ESR Bridges: imaging and treatment of hepatocellular carcinoma-a multidisciplinary view.
    Eur Radiol. 2024 Mar 15. doi: 10.1007/s00330-023-10579.
    

    >> Share

    
    

    
    Gut

23. TARGHER G, Byrne CD, Tilg H
    MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Gut. 2024;73:691-702.
    

    >> Share

    
    
24. HILDT E, Hu J
    New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
    Gut. 2024;73:566-567.
    

    >> Share

    
    

    
    Hepatology

25. PARK JG, Roh PR, Kang MW, Cho SW, et al
    Intrahepatic immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma.
    Hepatology. 2024 Feb 15. doi: 10.1097/HEP.0000000000000772.
    

    >> Share

    
    
26. STERLING RK, Asrani SK, Levine D, Duarte-Rojo A, et al
    AASLD Practice Guideline on non-invasive liver disease assessments of portal hypertension.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000844.
    

    >> Share

    
    
27. STERLING RK, Patel K, Duarte-Rojo A, Asrani SK, et al
    AASLD Practice Guideline on blood-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000845.
    

    >> Share

    
    
28. STERLING RK, Duarte-Rojo A, Patel K, Asrani SK, et al
    AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000843.
    

    >> Share

    
    
29. ROCKEY DC, Alsawas M, Rojo-Duarte A, Patel K, et al
    Non-invasive liver disease assessment to identify portal hypertension: A systematic review supporting the AASLD Practice Guideline.
    Hepatology. 2024 Mar 15. doi: 10.1097/HEP.0000000000000841.
    

    >> Share

    
    
30. DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al
    Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847.
    

    >> Share

    
    
31. MARCHETTI A, Pelusi S, Marella A, Malvestiti F, et al
    Impact of clonal hematopoiesis of indeterminate potential on hepatocellular carcinoma in individuals with steatotic liver disease.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000839.
    

    >> Share

    
    
32. BU W, Sun X, Xue X, Geng S, et al
    Early onset of pathological polyploidization and cellular senescence in hepatocytes lacking RAD51 creates a pro-fibrotic and pro-tumorigenic inflammatory microenvironment.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000821.
    

    >> Share

    
    
33. MUNOZ AE, Rodger EG
    Letter to the Editor: Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000846.
    

    >> Share

    
    
34. SHARPTON S, Loomba R
    Response to Letter to the Editor: emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Hepatology. 2024 Mar 11. doi: 10.1097/HEP.0000000000000848.
    

    >> Share

    
    

    
    Indian J Gastroenterol

35. RAMEGOWDA R, Gupta P
    Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review.
    Indian J Gastroenterol. 2024 Mar 9. doi: 10.1007/s12664-023-01511.
    

    >> Share

    
    

    
    Int J Cancer

36. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
    N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
    Int J Cancer. 2024;154:1857-1868.
    

    >> Share

    
    

    
    J Gastroenterol

37. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    

    >> Share

    
    

    
    J Hepatol

38. TOMLINSON JL, Li B, Yang J, Loeuillard E, et al
    Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma.
    J Hepatol. 2024 Mar 6:S0168-8278(24)00127-2. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
39. CHOI SH, Lee BM, Kim J, Kim DY, et al
    Efficacy of Stereotactic Ablative Radiotherapy in Patients with Oligometastatic Hepatocellular Carcinoma: A Phase II Study.
    J Hepatol. 2024 Mar 9:S0168-8278(24)00154-5. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
40. JACHS M, Sandmann L, Hartl L, Tergast T, et al
    Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    
41. MA AT, Sole C, Juanola A, Escude L, et al
    Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
    

    >> Share

    
    

    
    PLoS One

42. LI H, Wang C
    MIS-Net: A deep learning-based multi-class segmentation model for CT images.
    PLoS One. 2024;19:e0299970.
    

    >> Share

    
    
43. YAMASHITA T, Suzuki N, Motoyoshi K, Zhu W, et al
    Characteristics of patients with longer treatment period of lenvatinib for unresectable hepatocellular carcinoma: A post-hoc analysis of post-marketing surveillance study in Japan.
    PLoS One. 2024;19:e0298420.
    

    >> Share

    
    
44. KANEKO S, Asahina Y, Murakawa M, Azuma S, et al
    Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
    PLoS One. 2024;19:e0297882.
    

    >> Share

    
    

    
    Radiology

45. MOURA CUNHA G, Fan B, Navin PJ, Olivie D, et al
    Interpretation, Reporting, and Clinical Applications of Liver MR Elastography.
    Radiology. 2024;310:e231220.
    

    >> Share

    
    

    
    Transplant Proc

46. LIM WX, Sim KS, Chen CL, Ou HY, et al
    Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor Liver Transplantation.
    Transplant Proc. 2024 Mar 11:S0041-1345(24)00084.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share